Dave Ricks

Chair & CEO, Eli Lilly and Company · 2 appearances on the record.

computed by AI from the episodes · how this works → · full disclaimer →

executiveoperatorWikipedia ↗Instagram ↗

David A. Ricks has led Eli Lilly as CEO since 2017, overseeing its expansion into one of the world's most valuable pharmaceutical companies driven by blockbuster diabetes and obesity therapies like Mounjaro and Zepbound. Beyond Lilly, he serves on the board of directors of Adobe and the Purdue University Board of Trustees.

71statements → 57claims → 29claims resolved → 55%fully supported → 3.92/5average certainty → 2.03/5average debate potential → 4.2/5argument clarity · the sources → 1said about them ↓

16 supported 7 partly supported 6 contradicted 2 not yet assessed 26 not checkable as stated how the 57 claims stand · each chip opens the sources

12 predictions · 45 assertions · 3 opinions · 2 insights · 9 disclosures · every statement was checked. The predictions and assertions are the 57 claims: statements the public record can support or contradict. 29 are resolved, 2 are not yet assessed, and 26 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Dave argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Eli Lilly CEO: Tirzepatide surpassed Keytruda as best-selling drug ever
“And then terzepatide, which you asked how much money we're making, but in, actually in Q-two, we reported global sales, which surpassed Keytruda to becoming the best-selling drug in the world, actually the best-selling drug in the world of all time.”
Dave Ricks Sep 29, 2025 ▶ 3:11 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

Their most notable contradicted claim

Assertion Contradicted
Ricks: Eli Lilly's GLP-1 drugs are undefeated in chronic disease trials
“So far in our studies, this category of medicine's undefeated. We've never had an unsuccessful study in measuring an outcome in a chronic disease.”
Dave Ricks Oct 8, 2024 ▶ 25:00 Dave Ricks, CEO of Eli Lilly | The All-In Interview

Expressed certainty vs assessment result

none yet certainty 1
none yet certainty 2
75% certainty 3
59% certainty 4
78% certainty 5

weighted support: a fully supported claim counts one, a partly supported claim counts half. Each filled bar is clickable and opens exactly those claims; "none yet" means nothing said at that certainty level has resolved yet

Argument clarity: do they answer the question? how? →

4.2 / 5 directness 4.5 · coherence 4.6 · precision 4.3 · compression 3.8

redirected or did not address 1 of 12 assessed questions (8%). Watch them ▸

This is a score against a rubric. It is not a rank. Every host question → answer exchange is scored with names hidden on directness, coherence, precision and compression, 1–5 each, on meaning alone: disfluencies are ignored, and only raw unedited episodes count. This is the score that measures thought. Every scored exchange, scores shown → · The rubric and its checks →

How they sound: speaking style how? →

265 words/min while actually speaking · 17 um and uh per 1k words

Measured by listening to the audio itself: 12,023 words across 2 episodes of raw-level tape, transcribed verbatim with every um and uh kept, each one attributed only where the alignment onto our timed stream is unambiguous. These are measurements of speaking style. We do not rank them: across this corpus, fluency and argument quality are nearly uncorrelated (ρ≈0.2), and smooth talking does not signal clear thinking. How it's measured →

Everything Dave Ricks said on All-In that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Contradicted
Dave Ricks: Annual biotech venture funding collapsed from $20B to $5B
“Peak got to about twenty billion in new checks a year into biotech. We're now about five.”
Dave Ricks Sep 29, 2025 ▶ 12:45 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Partly supported
Dave Ricks: Half of public biotech companies trade at or below cash
“Half of biotech that's publicly traded is trading at or below cash.”
Dave Ricks Sep 29, 2025 ▶ 13:35 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Disclosure
Eli Lilly is starting trials for a brain-focused GLP-1 targeting mental health
“So we are now, right now, starting studies in bipolar disorder and major depressive disorder, along with these addictive hedonic pathways where you're sort of self-medicating and with a new GLP one, a different one, that probably, that has a little less weight…”
Dave Ricks Sep 29, 2025 ▶ 19:47 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Prediction Open · timeframe Sep 2029
Dave Ricks expects to launch a mental health GLP-1 in 3-4 years
“So we'll get that drug in three or four years if it works, and I think it could really change some of these terrible mental health conditions.”
Dave Ricks Sep 29, 2025 ▶ 20:07 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks: Most primary care doctors are too busy to stay updated
“Most primary care doctors are way too busy to even attend a continuing education, even know what's happening.”
Dave Ricks Sep 29, 2025 ▶ 24:04 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks: AI drug information is mostly accurate and substantially improved
“Mostly it's accurate, and they've It's gotten better over the last two years. I'd say substantially better.”
Dave Ricks Sep 29, 2025 ▶ 24:35 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Disclosure
Eli Lilly is transitioning its employee prescription coverage to a transparent PBM
“Actually, our company is moving to one.”
Dave Ricks Sep 29, 2025 ▶ 28:45 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Prediction Not checkable as stated
Dave Ricks predicts the next major therapeutic surprise will be brain disease
“It's hard to predict that, but I would say probably a brain disease.”
Dave Ricks Sep 29, 2025 ▶ 29:30 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks: Two-thirds of US calories are ultra-processed vs 35% in Europe
“In the U S we're now eating two thirds of our calories in our country are ultra processed. And that compares to like 35% in Europe.”
Dave Ricks Oct 8, 2024 ▶ 5:22 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Prediction Not checkable as stated
Dave Ricks: India's obesity rate projected to reach 30% within 20 years
“India, I think is 11% of the population's obese, but projected to go as much as 30% in the next 20 years.”
Dave Ricks Oct 8, 2024 ▶ 6:03 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Epic study links GLP-1 drug use to remarkably lower clinical depression rates
“There's an interesting study done by Epic. You know, they're the big health record company. Which is retrospective and not tightly controlled, but it showed people on GLP-I drugs, incretins, had remarkably lower rates of new clinical depression diagnoses, whic…”
Dave Ricks Oct 8, 2024 ▶ 8:52 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Dave Ricks: About 50% of employer-sponsored health plans cover GLP-1 weight-loss drugs
“Right now about 50% of the employer-sponsored insurance plans cover it.”
Dave Ricks Oct 8, 2024 ▶ 30:49 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Contradicted
Dave Ricks: Walmart study shows GLP-1 users buy 30% fewer calories
“Last year Walmart did this sort of what's in the cart study for people in Ozempic or Manjaro and it showed They were buying about a third less calories. So that's a lot, but that's consistent with how the drugs work. But interesting also, fewer salty snack foo…”
Dave Ricks Oct 8, 2024 ▶ 39:08 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Dave Ricks: 10 to 11 million Americans currently take GLP-1 drugs
“We only have 10 or eleven million Americans on these drugs.”
Dave Ricks Oct 8, 2024 ▶ 39:28 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Ricks: Eli Lilly GLP-1 launched at 20% discount to Novo Nordisk
“We launched at a 20% discount to Nova's product, even though we have better efficacy data, and we've only cut the price since then.”
Dave Ricks Oct 8, 2024 ▶ 45:44 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Opinion
Dave Ricks: CAR-T and gene therapies are difficult to scale to millions
“Those two techniques, CAR T and gene therapy, it's hard to think of like super scaled millions of people benefiting.”
Dave Ricks Oct 8, 2024 ▶ 52:33 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Insight
Ricks: Leaders cannot change corporate culture, only amplify positive traits
“When you're running a big ship like this, probably changing the culture is like beyond your capability. But what you can do is like extend, turn up the things that are good and turn down the things That are less good.”
Dave Ricks Oct 8, 2024 ▶ 57:40 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Eli Lilly spends $14.2 billion on R&D, equal to 25% of sales
“We spent 25% of sales on R&D. This year that'll be 14.2 billion dollars.”
Dave Ricks Sep 29, 2025 ▶ 9:00 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks: Pharma companies lack enduring franchises due to patent cliffs
“In pharma, all our, we have no enduring franchise. Everything we make goes to zero because of the patent system.”
Dave Ricks Sep 29, 2025 ▶ 9:34 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Prediction Open · timeframe Dec 2039
Dave Ricks predicts Mounjaro revenues will drop to zero in the 2030s
“So, in 20, 30 something, Manjaro will go to zero.”
Dave Ricks Sep 29, 2025 ▶ 9:47 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Disclosure
Eli Lilly is building six US plants and announcing four more
“We're currently constructing six plants. We're going to announce four more in the next six months.”
Dave Ricks Sep 29, 2025 ▶ 11:56 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Supported
Eli Lilly's Mounjaro demonstrated a 93% reduction in pre-diabetes conversion
“So we did that with Manjaro and showed a 93% reduction in conversion from pre-diabetes to diabetes.”
Dave Ricks Sep 29, 2025 ▶ 18:12 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks: The US is the least metabolically healthy large country
“I think we are the least healthy metabolic big country, and probably the reason for that is the food we feed ourselves.”
Dave Ricks Sep 29, 2025 ▶ 20:36 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Eli Lilly spends over half its consumer advertising budget outside TV
“By the way, more than half of our consumer spending to reach consumers is not on TV.”
Dave Ricks Sep 29, 2025 ▶ 22:58 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

Show 23statements(23 left)

The other half of the tape: Dave Ricks's own voice is left out of every number here. Other people bring the name up 1 time in 1 episode on All-In. every mention, with the transcript →

Who brings them up most Chamath Palihapitiya 1

Every mention by year

tap a year for its mentions
0011112024episodesmentions
0112024episodes it came up in
000.50.5112024episodesmentions per episode
2024 1 mention in 1 episode

Appearances (2)

EpisodeDateSpeaking time
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Sep 29, 2025 18m
Dave Ricks, CEO of Eli Lilly | The All-In Interview Oct 8, 2024 37m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 460 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.